DYDerya Yıldırım

Derya Yıldırım

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Derya Yıldırım has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comorbid Inflammatory Diseases in Behçet's Disease: A Multicenter Large Cohort Study

    by Emine Büşra Ata, İbRahim Yahya Çakır, Semiha Köroğlu, Gülay Alp, Mete Kara, Ebru Karaçalı, Fatih Mehmet Doğan, Yunus Emre Dalkılıç, Nuh Ataş, Derya Yıldırım, et al.

    Objectives: Behçet's disease (BD) is a chronic, multisystem immune‐mediated vasculitis. A significant number of patients with BD have inflammatory comorbid (IC) disease that can affect the clinical course of the disease. In the current literature, there is no study which investigated IC disease in BD. It was aimed to show the prevalence and clinical spectrum of IC disease in patients with BD. Methods: A total of 1591 patients diagnosed with BD and followed at five tertiary healthcare facilities were enrolled in the study. Patients were divided according to the presence of IC disease. Demographic characteristics, clinical manifestations, and laboratory parameters were systematically noted from medical records. The activity of the disease was evaluated by Behçet's Disease Current Activity Form (BDCAF). Results: Inflammatory comorbid diseases were identified in 246 (15.3%) patients. The most common comorbidities were axial spondyloarthritis ( n = 115, 7.2%), familial Mediterranean fever (FMF) ( n = 38, 2.4%), and hidradenitis suppurativa ( n = 37, 2.3%). Patients with IC disease had a greater use of anti‐TNF treatment ( p = 0.03). In the multivariate analysis, older age, and longer disease duration were found to be significantly associated with IC disease in BD ( p < 0.05). Conclusion: BD can be associated with other inflammatory conditions. Furthermore, patients with inflammatory comorbidities were more likely to receive anti‐TNF therapy, although this may partly reflect treatment indications for the comorbid conditions themselves. Therefore, clinicians should remain vigilant for inflammatory comorbidities, as their recognition may have implications for therapeutic decision‐making.

  • Open Access

    Interleukin‐40 in Systemic Sclerosis: A Treatment‐Sensitive Marker of Immune Modulation Rather Than Disease Activity

    by İbRahim Vasi, Emin Ümit Bağrıaçık, Rıza Can Kardaş, Nihan Örüklü, Melek Yaman, Derya Yıldırım, Burcugül Kaya, Rahime Duran, İbRahim Karaduman, İbRahim Yahya Çakır, et al.

    Interleukin‐40 (IL‐40) is a recently identified cytokine primarily produced by activated B cells and implicated in immune regulation across several autoimmune diseases. Although B cell–driven immune dysregulation plays a central role in systemic sclerosis (SSc), the circulating behavior and clinical relevance of IL‐40 in this disease remain poorly defined. To characterize serum IL‐40 levels in patients with SSc and to explore their associations with immunosuppressive treatment exposure, disease subsets, clinical manifestations, and disease activity. Serum IL‐40 levels were measured by ELISA in 41 patients with SSc and 29 age‐ and sex‐matched healthy controls. Patients were stratified according to immunosuppressive treatment status at the time of serum sampling. Clinical features, organ involvement, and disease activity were recorded. Serum IL‐40 levels differed significantly among immunosuppressed SSc patients, untreated SSc patients, and healthy controls ( p < 0.001). Patients receiving immunosuppressive therapy exhibited markedly lower IL‐40 concentrations compared with both untreated SSc patients and healthy controls. In contrast, untreated SSc patients showed IL‐40 levels comparable to controls. Serum IL‐40 levels were not significantly associated with cutaneous disease subtype, interstitial lung disease, dysphagia, or disease activity status. Stratified analyses demonstrated that lower IL‐40 levels in treated patients were observed irrespective of disease activity. Lower circulating IL‐40 levels were observed in immunosuppressed patients irrespective of disease phenotype, organ involvement, or disease activity. These findings support an association between treatment exposure and circulating IL‐40 levels, although longitudinal studies are needed to clarify causality.


  • Familial aggregation in Behçet’s Disease: Sibling history as a risk factor for Neuro-Behçet

    by Emine Büşra Ata, İbRahim Yahya Çakır, Asena Eken, Çetin Ergül, Ebru Karaçalı, Yunus Emre Dalkılıç, Fatih Mehmet Doğan, Emine Uslu, Nuh Ataş, Derya Yıldırım, et al.

  • Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network

    by Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Abdurrahman Tufan, Gaafar Ragab, Giuseppe Lopalco, Piero Portincasa, Donato Rigante, Sulaiman M Al-Mayouf, Ali Şahin, et al.

    Objectives: To assess the effectiveness of canakinumab (CAN) in controlling clinical and laboratory inflammation by achieving complete control of cardinal disease manifestations and full normalization of laboratory inflammatory markers. Methods: Data were obtained from the international AutoInflammatory Disease Alliance (AIDA) network registry, dedicated to monogenic autoinflammatory diseases. The assessment included both retrospective and prospective real-world data. Results: In total, 158 FMF patients treated with CAN were enrolled. Complete clinical-laboratory response was observed in 45.6% of patients at 3 months, 58.6% at 12 months and 55.2% at the last follow-up, after a mean treatment duration of 45 months. Partial response occurred in 16.5%, 12.5% and 16.8% at the same timepoints, respectively. Complete absence of clinical manifestations was observed in more than 80% of patients at each timepoint. Inflammatory markers normalized significantly by the 3-month assessment. The probability of achieving and maintaining complete response and full laboratory control appeared higher in patients reaching these outcomes by 3 months, although it remained substantial in other patients as well. Complete response was associated with a relapsing-remitting disease course and fewer annual attacks. Nearly all patients maintained stable organ damage scores, and therapy discontinuation due to inefficacy was rare (≤6%). Conclusion: CAN is effective in achieving rapid and sustained clinical and laboratory control in FMF, including stringent endpoints of complete response. Early effectiveness may favour better long-term outcomes, but delayed achievement of complete response and full laboratory control is not uncommon. This study confirms CAN as an effective, and durable therapeutic option in FMF.


  • Open Access

    Longitudinal clinical course and long-term outcomes of SLE-associated interstitial lung disease

    by Tuba Demirci Yıldırım, Berna Yurttaş, Aida Shikhaliyeva, Hasan Yardımcı, Reyhan Kose Cobanoglu, Burcu Yağız, Jehat Kılıç, Berkay Soysal, Deniz Dönmez, Derya Yildirim, et al.

  • Glomerulonephritis in Takayasu arteritis is dominated by mesangial and AA amyloid lesions and often arises during remission: a case-based review

    by Rıza Can Kardaş, Derya Yıldırım, Burcugül Kaya, İbRahim Vasi, Rahime Duran, Abdulsamet Erden, Hamit Küçük, Berna Göker, M. Akif Öztürk

    Takayasu arteritis (TAK) is a large-vessel vasculitis in which glomerulonephritis is a rare complication with a poorly characterized clinical and histopathological profile. Patients with biopsy-proven glomerulonephritis were retrospectively identified from a single-center TAK cohort followed between 2014 and 2022. A systematic review of PubMed/MEDLINE, Scopus, and Web of Science for articles published up to December 2025 was conducted in parallel, excluding studies involving patients younger than 18 years and cases with confounding autoimmune conditions or non-classifiable biopsy findings. This case-based review was reported in accordance with the CABARET and PRISMA 2020 standards. Among 72 patients with TAK, three (4.2%) had biopsy-proven glomerulonephritis. The systematic review yielded 31 articles describing 39 additional cases (84.6% female; median age at TAK diagnosis 26 years; median age at glomerular disease diagnosis 33 years). Glomerular disease was diagnosed a median of 5 years (IQR 0-11) after TAK and most often presented as asymptomatic proteinuria or nephrotic syndrome. Mesangial proliferative glomerulonephritis was the most common subtype (35.9%), followed by AA amyloidosis (30.8%), membranoproliferative glomerulonephritis (12.8%), focal segmental glomerulosclerosis (10.3%), and membranous nephropathy (7.7%). Renal artery stenosis was absent in 69.2% of cases. Corticosteroids were used in 92.3% of cases and biologic agents in 10.3%. Glomerulonephritis is a rare but clinically significant late complication of TAK, characterized by a distinct histopathological spectrum dominated by mesangial lesions, AA amyloidosis, and membranoproliferative glomerulonephritis. Routine proteinuria screening in patients with TAK, including during clinical remission, is warranted to enable early detection and timely management.

  • Open Access

    Prevalence of gout in the Sincan district of Ankara, Türkiye: a primary care-based cross-sectional study

    by Riza Can Kardaş, Yasemi̇n Ünsal, Derya Yildirim, Hakan Tüzün, Mustafa Necmi̇ İlHan, Hami̇t Küçük, Abdurrahman Tufan, M. Aki̇f Öztürk

    Background/aim: Gout, the most prevalent form of inflammatory arthritis, has shown a global increase in prevalence; however, data from Türkiye remain scarce, inconsistent, and largely confined to western regions. This study aimed to estimate the prevalence of gout among adults in the Sincan district of Ankara, Türkiye, and to provide updated data from a previously understudied region. Materials and methods: This cross-sectional, community-based study employed a multistage design. Adults aged ≥18 years who presented to selected family health centers in Sincan between February and June 2023 were screened using a structured questionnaire. Individuals with suspected gout underwent comprehensive clinical evaluation, including medical history, physical examination, and relevant laboratory testing, conducted by rheumatologists. Gout was classified according to the 2015 ACR/EULAR criteria, with a score of ≥8 required for classification. Results: Of the 517 individuals approached, 515 provided consent, and data from 513 participants were included in the final analysis. Screening identified 26 individuals with suspected gout, of whom 24 completed evaluation, resulting in the confirmation of seven gout cases (five men and two women). The overall estimated prevalence of gout was 1.36% (95% CI: 0.55%–2.81%). Prevalence was higher in men (2.18%; 95% CI: 0.71%–5.01%) than in women (0.70%; 95% CI: 0.09%–2.52%) although this difference was not statistically significant due to the small sample size, and prevalence increased with age. Conclusion: These findings provide updated epidemiological data, indicating a higher prevalence than previously reported in western Türkiye, while remaining within the lower range of global estimates. These data underscore the need to enhance gout awareness and to develop effective management strategies within the Turkish population.

  • Assessment of interstitial lung disease in systemic sclerosis using oscillometric methods: a novel approach to respiratory assessment

    by İbRahim Vasi, İbRahim Karaduman, Şeyma Alacaoğlu, Serra Duygulu, Rıza Can Kardaş, Derya Yıldırım, Burcugül Kaya, Rahime Duran, İbRahim Yahya Çakır, Esma Eseroğlu, et al.

    Objectives: Cardiopulmonary involvement is the leading cause of mortality in SSc, and early detection of interstitial lung disease (ILD) is critical to improving outcomes. Conventional spirometry has limitations, whereas impulse oscillometry (IOS) could provide a non-invasive, effort-independent method to detect and monitor pulmonary involvement in these patients. We aimed to evaluate IOS parameters in SSc-ILD, comparing their performance with conventional spirometry. Methods: This study assessed the detection of the presence and severity of ILD in SSc patients using conventional spirometry, diffusing lung capacity for carbon monoxide (DLCO), IOS, and high-resolution CT (HRCT). Results: Among 66 SSc patients, ILD was identified in 62.1%, with 26 patients having extensive and 15 limited ILD on HRCT. IOS demonstrated higher mean resonant frequency (Fres) in ILD-positive patients than in ILD-negative patients (22.95 ± 5.47 vs 15.01 ± 6.01, P = 0.001). Fres was also significantly higher in extensive ILD than in limited ILD and ILD-negative groups (P = 0.001 and P = 0.011, respectively). ROC analysis demonstrated that Fres achieved comparatively better diagnostic accuracy for detecting extensive ILD [area under the curve (AUC): 0.841, cut-off: 22.35, sensitivity: 73.1%, specificity: 85%], outperforming forced vital capacity (FVC) (% predicted) and DLCO (% predicted). For limited ILD, Fres showed moderate diagnostic performance (AUC: 0.752, cut-off: 17.42, sensitivity: 80%, specificity: 64%). Conclusion: Our findings indicate that impulse oscillometry, particularly Fres, may provide a non-invasive and effort-independent approach to assessing interstitial lung disease in SSc. Fres appeared to be related to radiological ILD extent and showed some diagnostic value, including in cases less evident by conventional spirometry.


  • Open Access

    A new characteristic of SLE: subclinical vein involvement–an in-depth biochemical and imaging study

    by Derya Yildirim, Abdulsamet Erden, Nemat Ibrahimkhanli, Elena Elefante, Rahime Duran, Handenur Koc Kanik, Rıza Can Kardas, İbRahim Vasi, Hazan Karadeniz, Mahinur Cerit, et al.

    Objectives: SLE is a heterogeneous autoimmune disorder often complicated by vascular events, with or without antiphospholipid antibody syndrome (APS). This study aimed to explore subclinical venous involvement in SLE using biochemical and imaging modalities, focusing on vein wall thickness (VWT) and inflammation-related biomarkers. Methods: In this cross-sectional study, 68 SLE patients were categorized based on antiphospholipid antibody (APA) status and clinical APS. Results were compared with 22 RA patients and 20 healthy controls. Serum levels of P-selectin, growth differentiation factor 15 (GDF15) and citrullinated histone 3 (CH3) were measured using ELISA. Ultrasonographic assessments evaluated VWT at bilateral jugular veins, femoral veins, portal vein and femoral artery. Correlations and predictors of vascular changes were analysed statistically. Results: VWT was significantly increased in SLE patients compared with both the control groups (P < 0.001), regardless of APA and APS status. Serum P-selectin, GDF15 and CH3 levels were elevated in SLE-APS patients. GDF15 levels correlated positively with VWT, and increased portal VWT was independently associated with thrombosis. Biomarkers showed significant associations with APS, suggesting their role as indicators of prothrombotic states. No significant associations were found between vascular parameters and disease activity score. Conclusion: Subclinical venous involvement appears to be a novel vascular feature of SLE, reflected by increased VWT and its association with thrombosis and biomarkers. Increased portal vein thickness may indicate vascular risk. Whether these changes result from inflammation or vascular remodelling remains unclear, but their presence irrespective of disease activity highlights their clinical relevance.


  • Open Access

    Evolution of Clinical Characteristics and Treatment Strategies in Turkish SLE Patients Over Two Decades: A Retrospective Cohort Study

    by Handenur Koç Kanık, Abdulsamet Erden, Derya Yıldırım, Arif Burak Kanık, Rahime Duran, Rıza Can Kardaş, Ibrahim Vasi, Burcugül Kaya, Hamit Küçük, Abdurrahman Tufan, et al.

    Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with diverse patterns of organ involvement, morbidity, and mortality. This study aimed to assess changes in demographic, clinical, and therapeutic characteristics of a single-center SLE cohort over the last two decades. Materials and methods: This retrospective study included 409 SLE patients from the Rheumatology Department at Gazi University Faculty of Medicine, meeting the 2019 EULAR/ACR classification criteria. Patients were categorized by diagnosis year into two groups: 1987–2012 and 2013–2023. Results: The proportion of male SLE patients increased approximately 2.5-fold in the last decade (5.2% vs. 12.6%, p = 0.008). While lupus nephritis rates remained stable, neurological (p = 0.012), hematological (p < 0.001), pulmonary (p < 0.001), and gastrointestinal (p < 0.001) involvements were significantly higher in the last decade. Use of mycophenolate mofetil (p = 0.036), methotrexate (p < 0.001), calcineurin inhibitors (p < 0.001), and rituximab (p < 0.001) increased, while steroid use (p = 0.044) and flare frequency (p = 0.035) decreased significantly. Although crude mortality rates improved (4.7% vs. 3.5%) without statistical significance (p = 0.54), male patients exhibited higher mortality rates than females (13.8% vs. 3.2%, p = 0.011). Hospitalization rates decreased but were not statistically significant (0.00130 vs. 0.00104/patient/year, p = 0.855). Conclusion: Over the last two decades, SLE management has evolved with improved therapeutic approaches and changing clinical manifestations. However, mortality remains disproportionately higher in male patients, underscoring the need for targeted interventions.